Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M94,258Revenue (TTM) $M11,229Net Margin (%)17.8Altman Z-Score4.2
Enterprise Value $M100,578EPS (TTM) $2.5Operating Margin %28.2Piotroski F-Score6
P/E(ttm)48.7Beneish M-Score-2.7Pre-tax Margin (%)21.1Higher ROA y-yN
Price/Book14.210-y EBITDA Growth Rate %--Quick Ratio3.5Cash flow > EarningsY
Price/Sales8.75-y EBITDA Growth Rate %16.1Current Ratio3.7Lower Leverage y-yY
Price/Free Cash Flow26.0y-y EBITDA Growth Rate %26.7ROA % (ttm)7.4Higher Current Ratio y-yN
Dividend Yield %--PEG3.0ROE % (ttm)34.7Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M778ROIC % (ttm)19.9Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

CELG is held by these investors:

CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
VESSEY RUPERTSee remarks 2016-11-22Sell2,500$123.18-1.64view
PEHL MICHAEL F.See remarks 2016-11-10Sell22,052$121.040.1view
Friedman Michael ADirector 2016-11-09Sell18,600$116.14.36view
HUGIN ROBERT Jsee remarks 2016-11-09Sell100,000$1200.97view
Friedman Michael ADirector 2016-10-03Sell56,116$103.6616.88view
MARIO ERNESTDirector 2016-09-23Sell15,000$109.4210.73view
BARKER RICHARD WDirector 2016-09-23Sell20,000$110.829.33view
KAPLAN GILLADirector 2016-09-15Sell9,710$106.4413.83view
LOUGHLIN JAMES JDirector 2016-08-23Sell27,500$114.16.19view
CASEY MICHAEL DDirector 2016-08-22Sell43,134$114.016.27view

Press Releases about CELG :

Quarterly/Annual Reports about CELG:

News about CELG:

Articles On GuruFocus.com
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Feb 14 2017 
Celgene Switzerland Invests in Jounce Therapeutics Feb 02 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Jan 24 2017 
9 Stocks Ray Dalio Continues to Buy Dec 22 2016 
When Is the PEG Ratio Superior to the P/E Ratio? Part 2 Nov 03 2016 
Abbott Develops AML Tests With Celgene and Agios Oct 13 2016 
Celgene: Is It a Buy? Jun 21 2016 
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
Gilead and Celgene Among Biotechnology Stocks to Buy May 26 2016 
DISH Network, H&R Block, Celgene, Plum Creek Timber Log Largest Insider Sells Jan 04 2016 

More From Other Websites
Celgene MS Drug Reports Positive Phase 3 Data Feb 20 2017
Forget Alexion, Buy these 4 Biotech Stocks Instead Feb 20 2017
7:30 am Celgene announces its phase III SUNBEAM trial, evaluating the efficacy and safety of... Feb 20 2017
Celgene MS Drug Wins In Trial; Will Safety Top Novartis, Biogen? Feb 17 2017
Stocks Quietly Mixed In Afternoon; Skyworks Breaks Out, Celgene Bases Feb 17 2017
Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial Feb 17 2017
CELGENE CORP /DE/ Files SEC form 8-K, Other Events Feb 17 2017
Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with... Feb 17 2017
Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y Feb 16 2017
Cramer fires back at naysayers: Here's your proof that th... Feb 15 2017
Proof the rally is real Feb 15 2017
CELGENE CORP /DE/ Financials Feb 15 2017
Celgene Could Have One More Powerful Move Higher Feb 15 2017
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia... Feb 14 2017
Celgene Corp. breached its 50 day moving average in a Bullish Manner : CELG-US : February 14, 2017 Feb 14 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)